Skip to content

Point-of-care testing of antiseizure medications and sex hormones based on nanopore technology

Point-of-care testing of antiseizure medications and sex hormones based on nanopore technology

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067504
Enrollment
Unknown
Registered
2023-01-10
Start date
2022-08-18
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Gold Standard:LC/MS technique is used as gold standard to detect the concentration of antiseizure medications in blood and saliva.
Index test:Nanopore sensor developed by our stduy is used as index test to detect the concentration of antiseizure medications in blood and saliva quantitatively.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with epilepsy; (2) Levetiracetam, lamotrigine, oxacepine or valproic acid have been taken regularly for more than 3 months; (3) Willing to participate in the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with serious diseases affecting the pahrmacology of antiseizure medications; (2) Patients concurrently taking other drugs that affect the pahrmacologyof antiseizure medications; (3) Patients who have irregular drug use in the past 3 months, with omissions, misadministration and other behaviors.

Design outcomes

Primary

MeasureTime frame
Concentrations of antiseizure medications;sensitivity;Accuracy;Specificity;

Countries

China

Contacts

Public ContactLei Chen

West China Hospital, Sichuan University

leilei_25@126.com18980605819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026